These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20829331)

  • 1. PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.
    Zhang CC; Yan Z; Zhang Q; Kuszpit K; Zasadny K; Qiu M; Painter CL; Wong A; Kraynov E; Arango ME; Mehta PP; Popoff I; Casperson GF; Los G; Bender S; Anderes K; Christensen JG; VanArsdale T
    Clin Cancer Res; 2010 Nov; 16(21):5177-88. PubMed ID: 20829331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
    Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
    Green SK; Karlsson MC; Ravetch JV; Kerbel RS
    Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
    Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
    J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis.
    Burden RE; Gormley JA; Jaquin TJ; Small DM; Quinn DJ; Hegarty SM; Ward C; Walker B; Johnston JA; Olwill SA; Scott CJ
    Clin Cancer Res; 2009 Oct; 15(19):6042-51. PubMed ID: 19789302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
    Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
    Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer.
    Howard EW; Ling MT; Chua CW; Cheung HW; Wang X; Wong YC
    Clin Cancer Res; 2007 Mar; 13(6):1847-56. PubMed ID: 17363541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
    Ran S; He J; Huang X; Soares M; Scothorn D; Thorpe PE
    Clin Cancer Res; 2005 Feb; 11(4):1551-62. PubMed ID: 15746060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer.
    Jiang PD; Zhao YL; Deng XQ; Mao YQ; Shi W; Tang QQ; Li ZG; Zheng YZ; Yang SY; Wei YQ
    Biomed Pharmacother; 2010 Nov; 64(9):609-14. PubMed ID: 20888174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
    Kurtzberg LS; Roth S; Krumbholz R; Crawford J; Bormann C; Dunham S; Yao M; Rouleau C; Bagley RG; Yu XJ; Wang F; Schmid SM; Lavoie EJ; Teicher BA
    Clin Cancer Res; 2011 May; 17(9):2777-87. PubMed ID: 21415217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.